MYC and neuroblastoma: This suggests further exploration of dosing conditions, or identification of optimum anti-mitotic/pro-apoptotic agents is required, for instance using biologically relevant testing platforms such as orthotopic patient-derived xenograft models for neuroblastoma and potentially other MYC(N) driven cancers.